164 related articles for article (PubMed ID: 35504423)
1. Naftopidil enantiomers suppress androgen accumulation and induce cell apoptosis via the UDP-glucuronosyltransferase 2B15 in benign prostate hyperplasia.
Zhan H; Zhang S; Li L; Chen Z; Cai Y; Huang J; Wu D; Huang B; Wu B; Liu X
J Steroid Biochem Mol Biol; 2022 Jul; 221():106117. PubMed ID: 35504423
[TBL] [Abstract][Full Text] [Related]
2. Pharmaceutical evaluation of naftopidil enantiomers: Rat functional assays in vitro and estrogen/androgen induced rat benign prostatic hyperplasia model in vivo.
Huang JJ; Cai Y; Yi YZ; Huang MY; Zhu L; He F; Liu XW; Huang BY; Yuan M
Eur J Pharmacol; 2016 Nov; 791():473-481. PubMed ID: 27615445
[TBL] [Abstract][Full Text] [Related]
3. Multiple roles for UDP-glucuronosyltransferase (UGT)2B15 and UGT2B17 enzymes in androgen metabolism and prostate cancer evolution.
Gauthier-Landry L; Bélanger A; Barbier O
J Steroid Biochem Mol Biol; 2015 Jan; 145():187-92. PubMed ID: 24861263
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.
Bao BY; Chuang BF; Wang Q; Sartor O; Balk SP; Brown M; Kantoff PW; Lee GS
Prostate; 2008 Jun; 68(8):839-48. PubMed ID: 18302198
[TBL] [Abstract][Full Text] [Related]
5. UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells.
Chouinard S; Barbier O; Bélanger A
J Biol Chem; 2007 Nov; 282(46):33466-33474. PubMed ID: 17848572
[TBL] [Abstract][Full Text] [Related]
6. Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis.
Jin BR; An HJ
Aging (Albany NY); 2020 Feb; 12(3):2142-2155. PubMed ID: 32018227
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic effects of Stauntonia hexaphylla in benign prostate hyperplasia are mediated by the regulation of androgen receptors and 5α-reductase type 2.
Hong GL; Park SR; Jung DY; Karunasagara S; Lee KP; Koh EJ; Cho K; Park SS; Jung JY
J Ethnopharmacol; 2020 Mar; 250():112446. PubMed ID: 31812646
[TBL] [Abstract][Full Text] [Related]
9. The role of dihydrotestosterone in benign prostatic hyperplasia.
Carson C; Rittmaster R
Urology; 2003 Apr; 61(4 Suppl 1):2-7. PubMed ID: 12657354
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate.
Barbier O; Bélanger A
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):259-70. PubMed ID: 18471784
[TBL] [Abstract][Full Text] [Related]
12. Loss of exogenous androgen dependence by prostate tumor cells is associated with elevated glucuronidation potential.
Zimmer BM; Howell ME; Wei Q; Ma L; Romsdahl T; Loughman EG; Markham JE; Seravalli J; Barycki JJ; Simpson MA
Horm Cancer; 2016 Aug; 7(4):260-71. PubMed ID: 27307252
[TBL] [Abstract][Full Text] [Related]
13. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of two uridine diphospho-glucuronosyltransferases, UGT2B15 and UGT2B17, in human prostate LNCaP cells.
Guillemette C; Lévesque E; Beaulieu M; Turgeon D; Hum DW; Bélanger A
Endocrinology; 1997 Jul; 138(7):2998-3005. PubMed ID: 9202245
[TBL] [Abstract][Full Text] [Related]
15. Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5-α-reductase.
Tao R; Miao L; Yu X; Orgah JO; Barnabas O; Chang Y; Liu E; Fan G; Gao X
J Ethnopharmacol; 2019 May; 235():65-74. PubMed ID: 30708032
[TBL] [Abstract][Full Text] [Related]
16. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
[TBL] [Abstract][Full Text] [Related]
17. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
Krieg M; Bartsch W; Thomsen M; Voigt KD
J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
[TBL] [Abstract][Full Text] [Related]
18. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
19. Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.
Grosse L; Pâquet S; Caron P; Fazli L; Rennie PS; Bélanger A; Barbier O
Cancer Res; 2013 Dec; 73(23):6963-71. PubMed ID: 24121496
[TBL] [Abstract][Full Text] [Related]
20. Quisqualis indica Improves Benign Prostatic Hyperplasia by Regulating Prostate Cell Proliferation and Apoptosis.
Ub Wijerathne C; Park HS; Jeong HY; Song JW; Moon OS; Seo YW; Won YS; Son HY; Lim JH; Yeon SH; Kwun HJ
Biol Pharm Bull; 2017 Dec; 40(12):2125-2133. PubMed ID: 28943529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
